Click for a HEPATIQ free trial

2024

December 12, 2024 - Before an intervention, individualized assessment should be carried out in patients with poorer liver functional reserve
If you are attending the Society of Interventional Oncology (SIO) conference Jan 30 – Feb 3 in Las Vegas, please visit our booth 107 to learn more about HEPATIQ® - The Ultimate Liver Test™. We are offering new customers a 6 month free trial of up to 50 HEPATIQ reports worth $4,750. There is no obligation to buy after the free trial.
A 2022 publication in the Journal of Hepatology, “The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma”, by D’Avola et al, states that “Patients with compensated cirrhosis and large liver functional reserve can always receive the most radical treatment”. However, “a more detailed and individualized assessment should be carried out in patients with poorer liver functional reserve”. The HEPATIQ test’s PHM (perfused hepatic mass) and fLV (functional liver volume) indices provide a measure of the liver functional reserve.[7,11,13,14,15,18,19,20,22,24,28]
The case for individualized assessments is illustrated here by the HEPATIQ images shown for an 82 year old female cirrhotic patient who developed hepatocellular carcinoma (HCC).
As the HEPATIQ fLV-PHM differential graph below shows, when she was first assessed for liver function she was an H2 and remained so for more than three years before progressing to H3. After her HCC was detected, she was treated with radio frequency ablation (RFA). However, the cancer returned and she was then treated with Y90 radio embolization.
Unfortunately, the cancer returned again and she was re-treated with Y90. She had progressed to H4 by that time and after the second Y90 treatment she developed ascites, hepatic encephalopathy and subsequently died.
November 28, 2024 - Boost Revenues with a New SPECT Application - HEPATIQ
If you are attending the RSNA conference December 1-4 in Chicago, please visit our booth 1503 to learn more about HEPATIQ® - The Ultimate Liver Test™. We are offering new customers a 6 month free trial of up to 50 HEPATIQ reports worth $4,750. Alternatively, sign up for the free trial at www.hepatiq.com. There is no obligation to buy after the free trial.
To use HEPATIQ, simply perform a standard liver SPECT scan with Technetium-99m sulfur colloid. We will process the SPECT images and produce the HEPATIQ report for you. HEPATIQ is cleared by the FDA and the SPECT scan is reimbursable by insurance under CPT 78803. HEPATIQ uses existing scanners, isotope, infrastructure and staff to provide better liver disease diagnosis and prognosis [1-28] while generating significant additional revenues for nuclear medicine. Medicare pays about $1,400 for the SPECT scan and private insurance more. Performing one liver SPECT per day can generate about $350,000 of additional revenue per year from your SPECT scanner.
October 31, 2024: Visit AASLD booth 1147 for a free trial of HEPATIQ® - The Ultimate Liver Test™
HEPATIQ provides a management option for the physician caring for a liver disease patient who tests abnormal on a blood test or elastography. The patient may in fact be healthier or sicker than the fibrosis measurements suggest (Hagström et al, Gastroenterology, Jan 2020; and Singh et al, Journal of Clinical Gastroenterology, Nov 2020). HEPATIQ may be used to assess liver functional reserve for such patients. Furthermore, any patient needing treatment for liver cancer would benefit from an assessment of liver functional reserve prior to an intervention or surgery (D’Avola et al, Journal of Hepatology, 2022).
HEPATIQ provides six indices of liver disease from a single 20 minute SPECT scan: quantitative liver function, steatosis/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size.[1-27] HEPATIQ also calculates a physiologic stage of liver disease [28]: H0: Normal liver function, H1: Borderline liver function, H2: Steatotic cirrhosis likely, H3: Non-steatotic cirrhosis likely, H4: Liver decompensation likely, and H5: Liver transplant candidate. HEPATIQ is the only product on the market that precisely and non-invasively quantifies liver functional reserve. Other techniques such as biopsies, elastography and blood tests estimate liver fibrosis but do not quantify function. Research shows that function outperforms fibrosis in the prediction of outcomes. [5,7,12,13,16,17,21,22,24] Fibrosis measurements lack strong predictive power because liver disease outcomes are driven by the liver functional reserve, not the extent of fibrosis. The diseased liver compensates by generating new functioning lobules and instigating increased blood flow – a hemodynamic phenomenon missed by fibrosis measurements.[8]
The HEPATIQ indices are used for diagnosis, staging, interventions, and monitoring liver disease progression. They help identify those at risk of ascites, variceal bleeding, hepatic encephalopathy and liver-related death.[5,7] The numbers in square brackets are references to publications listed at www.hepatiq.com/publications/.
September 2, 2024: Visit ASTRO booth 808 for the latest research on HEPATIQ
If you are attending the ASTRO conference in Washington DC, please visit our booth 808 to learn more about HEPATIQ® - The Ultimate Liver Test™. A 2022 publication in the Journal of Hepatology, “The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma”, by D’Avola et al, states that “Patients with compensated cirrhosis and large liver functional reserve can always receive the most radical treatment”. However, “a more detailed and individualized assessment should be carried out in patients with poorer liver functional reserve”. The HEPATIQ test’s PHM and fLV indices provide a measure of the patient’s liver functional reserve. [7,11,13,14,15,18,19,20,22,24,28]
  • HEPATIQ provides six indices of liver disease from a single 20 minute SPECT scan: quantitative liver function, steatosis/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size.[1-27] HEPATIQ also calculates a physiologic stage of liver disease [28]: H0: Normal liver function, H1: Borderline liver function, H2: Steatotic cirrhosis likely, H3: Non-steatotic cirrhosis likely, H4: Liver decompensation likely, and H5: Liver transplant candidate.
  • HEPATIQ is the only product on the market that precisely and non-invasively quantifies liver functional reserve. Other techniques such as biopsies, elastography and blood tests estimate liver fibrosis but do not quantify function. Research shows that function outperforms fibrosis in the prediction of outcomes. [5,7,12,13,16,17,21,22,24] Fibrosis measurements lack strong predictive power because liver disease outcomes are driven by the liver functional reserve, not the extent of fibrosis. The diseased liver compensates by generating new functioning lobules and instigating increased blood flow – a hemodynamic phenomenon missed by fibrosis measurements.[8]

  • The HEPATIQ indices are used for diagnosis, staging, interventions, and monitoring liver disease progression. They help identify those at risk of ascites, variceal bleeding, hepatic encephalopathy and liver-related death.[5,7] The numbers in square brackets are references to publications listed at www.hepatiq.com/publications/.